Status:
COMPLETED
Study of Cetuximab in Combination With Tarceva in Patients With Solid Tumors
Lead Sponsor:
Eli Lilly and Company
Conditions:
Neoplasms
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to find a safe and effective dose of the combination of cetuximab (Erbitux) and Tarceva (erlotinib).
Eligibility Criteria
Inclusion
- Measurable disease
- Life expectancy of at least 3 months
- Must have at least one prior chemotherapy containing a platinum
Exclusion
- Known or documented brain metastases
- Prior cetuximab therapy
Key Trial Info
Start Date :
August 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2007
Estimated Enrollment :
33 Patients enrolled
Trial Details
Trial ID
NCT00207077
Start Date
August 1 2005
End Date
May 1 2007
Last Update
October 28 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Christiana Care Health Services, Inc.
Newark, Delaware, United States, 19718